Afamelanotide in managing cutaneous phototoxicity in erythropoietic protoporphyria: a Scottish perspective

Le résumé fourni par la source

Erythropoietic protoporphyria (EPP) is a rare but severely debilitating photodermatosis triggered by exposure to visible and longwave ultraviolet A light, causing intense and prolonged pain that leads to extreme sunlight avoidance and a markedly reduced quality of life. Afamelanotide, the only licensed medication for EPP phototoxicity, is currently being assessed under the Scottish Medicines Consortium’s ultra-orphan pathway, which supports access to treatments for very rare conditions. This is the first report of afamelanotide use in patients with EPP in Scotland. It demonstrates a significant improvement in the time that patients with EPP can spend in sunlight without experiencing painful symptoms and significantly enhancing their overall quality of life.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.